Inhibitors of cathepsin C (dipeptidyl peptidase I)

Bibliography

• Turk D, Janjic V, Stern I, Structure of human dipetidyl peptidase I (cathepsin C): exclusion domain added to an endopeptidase framework creates the machine for activation of granular serine protease. EMBO J 2001;20:6570-82
   PubMed Web of Science ®Google Scholar
• McGuire MJ, Lipsky PE, Thiele DL. Purification and characterization of dipeptidyl peptidase I from human spleen. Arch Biochem Biophys 1992;295:280-8
   PubMedGoogle Scholar
• Tran TV, Ellis KA, Kam C-M, Dipeptidyl peptidase I: importance of progranzyme activation sequences, other dipeptide sequences, and the N-terminal amino group of synthetic substrates for enzyme activity. Arch Biochem Biophys 2002;403:160-70
   PubMedGoogle Scholar
• McDonald KJ, Zeitman BB, Reilly TJ, Ellis S. New observations on the substrate specificity of cathepsin C (dipeptidyl aminopeptidase I). J Biol Chem 1969;244:2693-709
   PubMed Web of Science ®Google Scholar
• McDonald JK, Callahan PX, Ellis S. Preparation and specificity of dipeptidyl aminopeptidase I. Methods Enzymol 1972;25:272-81
   PubMedGoogle Scholar
• Molgaard A, Arnau J, Lauritzen C, The crystal structure of human dipeptidyl peptidase I (cathepsin C) in complex with the inhibitor Gly-Phe-CHN2. Biochem J 2007;401:645-50
   PubMedGoogle Scholar
• Kominami E, Ishido D, Muon D, Sato N. The primary structure and distribution of cathepsin C. Biol Chem Hoppe Seyler 1992;373:367-73
   PubMedGoogle Scholar
• Mallen-St Clair J, Pham CT, Villalta SA, Mast cell dipeptidyl peptidase I mediates survival from sepsis. J Clin Invest 2004;13:628-34
   Google Scholar
• Adkison AM, Raptis SZ, Kelley DG, Pham CTN. Dipeptidyl peptidase I activates neutrophil-derived serine proteases and regulates the development of acute experimental arthritis. J Clin Invest 2002;109:363-71
   PubMed Web of Science ®Google Scholar
• Methot N, Rubin J, Guay D, Inhibition of the activation of multiple serine proteases with a cathepsin C inhibitor requires sustained exposure to prevent pro-enzyme processing. J Biol Chem 2007;282:20836-46
   PubMedGoogle Scholar
• Methot N, Guay D, Rubin J, In vivo inhibition of serine protease processing requires a high fractional inhibition of cathepsin C. Mol Pharmacol 2008;73:1857-65
   PubMedGoogle Scholar
• McGuire MJ, Lipsky PE, Thiele DL. Generation of active myeloid and lymphoid granule serine proteases requires processing by the granule thiol protease dipeptidyl petidase I. J Biol Chem 1993;268:2458-67
   PubMed Web of Science ®Google Scholar
• Mabee CL, McGuire MJ, Thiele DL. Dipeptidyl peptidase I and granzyme A are coordinately expressed during CD8+ T cell development and differentiation. J Immunol 1998;160:5880-5
   PubMedGoogle Scholar
• Thiele DL, McGuire MJ, Lipsky PE. A selective inhibitor of dipeptidyl peptidase I impairs generation of CD8+ T cell cytotoxic effector function. J Immunol 1997;158:5200-10
   PubMedGoogle Scholar
• Bidere N, Briet M, Durrbach A, Selective inhibition of dipeptidyl peptidase I, not caspases, prevents the partial processing of procaspase-3 in CD3-activated human CD8+ T lymphocytes. J Biol Chem 2002;277:32339-47
   PubMedGoogle Scholar
• Pagano MB, Bartoli MA, Ennis TL, Critical role of dipeptidyl peptidase I in neutrophil recruitment during the development of experimental abdominal aortic aneurysms. Proc Natl Acad Sci 2007;104:2855-60
   PubMed Web of Science ®Google Scholar
• Wolter PJ, Pham CTN, Muilenburg DJ, Ley TJ. Dipetidyl peptidase I is essential for activation of mast cell chymases, but not tryptases in mice. J Biol Chem 2001;276(21):18551-6
   PubMedGoogle Scholar
• Pham CT, Ley T. Dipetidyl peptidase I is required for the processing and activation of granzymes A and B in vivo. Proc Natl Acad Sci 1999;96:8627-32
   PubMed Web of Science ®Google Scholar
• Kim S, Nadel JA. Role of neutrophils in mucus hypersecretion in COPD and implications for therapy. Treat Respir Med 2004;3:147-59
   PubMedGoogle Scholar
• Novartis. Organic compounds. WO2007045476; 2007
   Google Scholar
• Dhanrajani PJ. Papillion-Lefevre syndrome: clinical presentation and a brief review. Oral Surg Oral Med Oral Patho Oral Radiol Endod 2009;108:e1-7
   Web of Science ®Google Scholar
• Zeeuwen PLJM. Epidermal differentiation: the role of proteases and their inhibitors. Eur J Cell Biol 2004;83:761-73
   PubMedGoogle Scholar
• University of Texas. Dipeptidyl peptidase-1 inhibitors and uses thereof. US5602102; 1997
   Google Scholar
• Green GDJ, Shaw E. Peptidyl diazomethyl ketones are specific inactivators of thiol protinases. J Biol Chem 1981;256:1923-8
   PubMed Web of Science ®Google Scholar
• Korver GE, Kam C-M, Powers JC, Hudig D. Dipeptide vinyl sulfones suitable for intracellular inhibition of dipeptidyl peptidase I. Int Immunopharm 2001;1:21-32
   PubMedGoogle Scholar
• Thompson SA, Andrews PR, Hanzlik RP. Caboxyl-modified amino acids and peptides as protease inhibitors. J Med Chem 1986;29:104-11
   PubMed Web of Science ®Google Scholar
• Kam C-M, Götz MG, Koot G, Design and evaluation of inhibitors for dipeptidyl peptidase I (Cathepsin C). Arch Biochem Biophys 2004;427:123-34
   PubMedGoogle Scholar
• Georgia Tech Research Corp. Peptidyl allyl sulfones. US20060241057; 2006
   Google Scholar
• Probiodrug AG. Novel inhibitors of dipeptidyl peptidase I. WO2003022871; 2003
   Google Scholar
• Combio A/S. Protease inhibitorsWO2004110988; 2004
   Google Scholar
• AstraZeneca. Peptidyl nitriles and use thereof as dipeptidyl peptidase I inhibitors. WO2009074829; 2009
   Google Scholar
• Guay D, Beaulieu C, Reddy TJ, Bioorg Med Chem Lett 2009;19:5392-96
   PubMedGoogle Scholar
• Falgueyret J-P, Oballa RM, Okamoto O, Novel, nonpeptidic cyanamides as potent and reversible inhibitors of human cathepsins K and L. J Med Chem 2001;44:94-104
   PubMed Web of Science ®Google Scholar
• Rydzewki RM, Bryant C, Oballa R, Peptidic 1-cyanopyrrolidines: synthesis and SAR of a series of potent, selective cathepsin inhibitors. Bioorg Med Chem 2002;10:3277-84
   PubMedGoogle Scholar
• GlaxoSmithKline. Preparation of pyrazolidine, hexahydropyridazine, and hexahydro-1H-1,2-diazepine nitriles as cathepsin C inhibitors. WO2006094003; 2006
   Google Scholar
• GlaxoSmithKline. Cathepsin C inhibitors. WO2009129371; 2009
   Google Scholar
• GlaxoSmithKline. Cathepsin C inhibitors. WO2009129365; 2009
   Google Scholar
• GlaxoSmithKline. Cathepsin C inhibitors. WO2009129370; 2009
   Google Scholar
• GlaxoSmithKline. Preparation of novel N-(1-cyano-5-substituted pyrrolidin-3-yl)benzenesulfonamides as cathepsin C inhibitors and their use for treating chronic obstructive pulmonary disease. WO2009026197; 2009
   Google Scholar
• Combio A/SProtease inhibitorsWO2004106289; 2004
   Google Scholar
• Bondebjerg J, Fuglsang H, Valeur KR, Novel semicarbazide-derived inhibitors of human dipeptidyl peptidase I (hDDPI). Bioorg Med Chem 2005;13:4408-24
   PubMed Web of Science ®Google Scholar